


Respiratory Pathogens Data Jul 09- Oct 28 2017


Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI %FLU	EIA %FLU
OCT 22	0	1	0	0	3	35	79	1	1	12	3	0	0	135	1	360	0.3	2.9	0.9	1.1
OCT 14	0	0	0	0	3	24	59	1	2	2	2	0	1	94	0	364	0.0	2.5	0.9	1.6
OCT 8	0	0	1	0	6	33	91	3	0	2	0	2	0	138	1	333	0.3	2.7	1.0	1.1
Oct 01	0	0	0	0	1	18	73	1	3	0	2	1	0	99	0	340	0.0	2.0	1.0	1.1
SEPT 24	0	0	0	0	1	24	79	0	3	3	3	0	0	113	0	286	0.0	1.6	1.2	1.7
SEPT 17	0	0	0	0	3	9	93	1	4	0	3	1	0	114	0	314	0.0	1.6	1.3	3.5
SEP 9	0	0	0	0	0	18	94	3	2	2	0	0	0	119	0	359	0.0	1.7	1.5	1.8
SEP 2	0	0	1	0	0	12	49	0	5	1	1	1	0	70	1	234	0.4	1.8	1.1	2.7
AUG 27	0	0	2	0	1	14	62	1	4	1	2	0	0	87	2	252	0.8	1.9	0.9	1.6
AUG 20	0	1	0	1	0	11	28	3	1	3	1	1	1	51	2	215	0.9	1.7	0.8	4.2
AUG 13	0	0	2	0	0	8	32	2	3	2	3	0	1	53	2	196	1.0	2.3	1.0	3.6
AUG 6	0	0	0	0	1	10	30	1	1	1	1	1	1	47	0	211	0.0	2.2	1.2	0.0
JULY 30	0	0	0	0	0	7	32	4	0	1	0	0	0	44	0	214	0.0	2.4	1.4	0.0
JULY 23	0	0	0	0	0	9	17	1	2	2	0	0	0	31	0	197	0.0	2.1	0.6	0.0
JULY 16	0	0	0	2	0	5	21	4	2	0	0	1	0	35	0	187	1.1	2.4	0.9	0.0
JULY 9	0	0	0	0	0	12	37	6	2	1	2	1	0	61	0	222	0.0	1.8	0.8	6.7

Flu PCR
% Rate


ACL RESP. PANEL - POSITIVITY RATE All targets 37.5%



ACL Influenza PCR POS 0.3%




ACL FLUAG EIA POS 1.1%



CDC Oct 28, 2017 Positivity rate 2.9% - Flu A – 91% (2009 H1N1 -13% , seasonal H3 -81%) Flu B – 8%


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 2, 2016 – October 28, 2017



A Weekly Influenza Surveillance Report Prepared by the Influenza Division


Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

Week Ending Oct 28, 2017 - Week 43




*This map indicates geographic spread and does not measure the severity of influenza activity.


The most prevalent target as Oct 21st is; Low level of NORO GI virus



TOTAL VOLUME vs BP POS Sep 6.1%



TOTAL VOL vs NoV POS - Sep 4.8%



Neuraminidase Inhibitors Resistance - During May 21-October 28, 2017, 436 specimens (61 influenza A(H1N1)pdm09, 250 influenza A(H3N2), and 125 influenza B viruses) collected in the United States were tested for susceptibility to the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir). **All tested viruses were sensitive** to all three recommended antiviral medications.

Update Aug- 2017 PAHO/CDC

Target	Source	Period	CDC	US % POS	ACL 2017
Locally acquired	US (endemic)	Jan 2017-Aug 2017	0	0.00	
Zika virus US import	US (travelers)	Jan 2017-Aug 2017	185	0.06	4
Zika virus US territory.	US (local)Puerto Rico	Jan 2017-Aug 2017	553	0.15	0
Dengue US import	US (travelers)	07/31/17	62	0.02	3
Dengue US territory	US (local)Puerto Rico ⁹	07/31/17	9	0.00	0
Chikungunya US import	US (travelers)	Jan 2017-Aug 2017	20	0.01	1
Chikungunya US territory	US (local)Puerto Rico	Jan 2017-Aug 2017	15	0.00	0